MedPath

Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie

Conditions
Botulinum Toxin for the Treatment of Depression
Registration Number
EUCTR2009-015125-36-DE
Lead Sponsor
Medical School Hannover. Department of Psychiatry, Social Psychiatry and Psychotherapy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Mild to moderate depression (Ham-D >=15)
Therapy with one or two antidepressants for at least four weeks
at least moderate frown line
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Bipolar depression
Psychiatric comorbidity
Severe somatic comorbidity
Pregnancy
Peculiarities at the injection site
Psychiatric medication other than one or two antidepressants
Specific psychotherapy
Previous application of botulinum toxin
Medication interfering with botulinum toxin

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath